Skip to main content
Home > BioCentury on BioBusiness > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Table: New products to watch

    Milestones galore New products to watch Selected drugs that received regulatory approval in 2014. (A) Prior approvals in parentheses; (B) Being acquired by Merck & Co. Inc. (NYSE:MRK); Source: BCIQ: BioCentury …

    Published on 1/12/2015
  • Table: Post-launch report

    Milestones galore Post-launch report Three products that were first approved in 2013 have already recorded 2014 sales over $1 billion each. Two of them are oral HCV drugs — Sovaldi sofosbuvir from Gilead Sciences …

    Published on 1/12/2015
  • Table: Top biotech products

    Milestones galore Top biotech products At least 28 drugs developed and marketed by biotechs are expected to have more than $1 billion in 2014 sales. Antivirals from Gilead Sciences Inc. (NASDAQ:GILD) account for …

    Published on 1/12/2015
  • Figure: London vs. Europe

    Grow early, grow often London vs. Europe Both the BioCentury Europe and the BioCentury London indexes ended the year up more than 16%. The BC Europe posted a 24% gain, with advancers beating decliners 12-7. The …

    Published on 1/5/2015
  • Figure: Results by market cap

    Grow early, grow often Results by market cap The top market cap tier — companies valued above $5 billion — outperformed all other market cap segments in 2014, gaining 32% on the year. Of the 31 companies in the …

    Published on 1/5/2015
  • Table: 4Q approvals and setbacks

    Grow early, grow often 4Q approvals Selected fourth quarter approvals. (A) Cubist Pharmaceuticals Inc. (NASDAQ:CBST) is being acquired by Merck & Co. Inc. (NYSE:MRK) Company Approval AbbVie Inc. (NYSE:ABBV)/…

    Published on 1/5/2015
  • Table: Index performance

    Grow early, grow often Index performance The BioCentury 100, NYSE Arca Biotechnology (BTK) and NASDAQ Biotechnology (NBI) indices all ended the year well ahead of the general market benchmarks. The BC100 lagged …

    Published on 1/5/2015
  • Table: Restructuring watch

    Grow early, grow often Restructuring watch At least two companies reported workforce reductions in the fourth quarter compared to at least 13 in the same period last year. Tied with 1Q14, this is the smallest …

    Published on 1/5/2015
  • 2015 Financial Markets Preview: Show me in 2015

    How buysiders expect maturing sector to deliver growth in 2015

    Buysiders expect 2015 to be driven by mature large caps while follow-ons will be open for small caps that deliver on expectations.

    Published on 1/5/2015
  • Figure: Healthcare/biotech fund flows

    Show me in 2015 Healthcare/biotech fund flows More than $6 billion flowed into healthcare/biotech funds last quarter, bringing net fund flows to $18 billion for the year. The S&P 500 Health Care Index gained 7% …

    Published on 1/5/2015
  • Figure: M&A activity

    Show me in 2015 M&A activity The aggregate transaction value for M&A deals completed in 2014 reached a record $86 billion, beating the previous high of $80 billion in deals in 2011 and more than 2.6x the $32.5 …

    Published on 1/5/2015
  • Figure: Price-to-earnings: BT vs RX

    Grow early, grow often Price-to-earnings: BT vs RX The average biotech P/E ended the year at 22.4, about 1.3x the 17.7 average for big pharma. A year ago, biotech's P/E was 1.6x big pharma's multiple. The 13% …

    Published on 1/5/2015
  • Figure: Raised by market cap

    Show me in 2015 Raised by market cap In 2014, 467 public companies raised $45.5 billion vs. 401 companies that raised $31.2 billion in 2013. The increase was bolstered by large debt financings from a handful of …

    Published on 1/5/2015
  • Table: Follow-on performance

    Show me in 2015 Follow-on performance In 2014, $11 billion was raised via 150 follow-on offerings, above the $10 billion raised from 139 deals in 2013. The 2014 class is up a median of 14% from their postmoney …

    Published on 1/5/2015
  • Table: IPO performance

    Show me in 2015 IPO performance Twenty-three companies raised $2.1 billion in IPOs in 4Q14, bringing the total for 2014 to 112 companies that raised $9 billion. In 2013, 60 IPOs raised $3.9 billion. The median …

    Published on 1/5/2015
  • Table: IPO queue

    Show me in 2015 IPO queue Fourteen companies have announced plans to go public since the start of 4Q14, bringing the IPO queue to at least 31. Unless noted, companies are seeking to list on NASDAQ. (A) If proposed…

    Published on 1/5/2015
  • 4Q14 Stock Wrap-up: Grow early, grow often

    Winners, losers in biotech stock tiers in 4Q14

    Biotech stocks rose in all but the microcap tier in 4Q14, with strong showings by recent IPO companies.

    Published on 1/5/2015
  • Targeting access

    How ASCO, Palmetto propose to use cancer genomics to choose off-label therapies

    How ASCO and the Palmetto-backed Molecular Evidence Development Consortium propose to use cancer genomics to choose and study off-label therapies.

    Published on 12/22/2014
  • Table: TAPUR vs. MED-C

    Targeting access TAPUR vs. MED-C The American Society of Clinical Oncology and the Molecular Evidence Development Consortium (MED-C) are launching registries to collect evidence about biomarker-based off-label use…

    Published on 12/22/2014
  • Figure: Legal complexity

    Momenta moving on Legal complexity Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) had hoped its platform for characterizing complex molecules would create IP and know-how that would protect a portfolio of complex …

    Published on 12/15/2014
  • Momenta moving on

    Why Momenta abandoning complex generics in favor of novel drugs and biosimilars

    Momenta unveils its novel drug, biosimilar strategy after nine years of legal and regulatory setbacks in complex generics.

    Published on 12/15/2014
  • Pricing gene therapies

    Lessons from Glybera on alternative pricing models for gene therapies

    Disease-specific issues stymied annuity pricing for uniQure's Glybera, but the model still could work for gene therapies in other diseases.

    Published on 12/8/2014

    Merck's IMPROVE-IT bolsters case for PCSK9 inhibitors, but sets bar for outcomes

    Merck's IMPROVE-IT shows nonstatin LDL-lowering improves CV outcomes, but also sets outcomes hurdles for PCSK9 agents poised in the wings.

    Published on 11/24/2014
  • Poste a pourvoir

    Board mandates mean shoring up Lantus losses won't be easy for Sanofi CEO

    Sanofi's new CEO will have a hard row to hoe to offset Lantus declines, as the board has taken easy solutions off the table.

    Published on 11/17/2014
  • Figure: Pipeline by source

    Poste à pourvoir Pipeline by source During his tenure as CEO of Sanofi (Euronext:SAN; NYSE:SNY), Chris Viehbacher and President of Global R&D Elias Zerhouni pruned the pharma's pipeline of uncompetitive programs and…

    Published on 11/17/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993